Immix to Present NXC-201 Data at ASH
Immix Biopharma will present 45-patient NXC-201 safety and efficacy data at the 68th ASH Annual Meeting in New Orleans.
Updated on Nov. 4, 2026 in Healthcare
Immix Biopharma announced that an abstract on NXC-201 will be presented at the 68th ASH Annual Meeting and Exposition, held December 12-15, 2026, in New Orleans, Louisiana. The oral presentation, covering 45-patient safety and efficacy data from the Nexicart-2 trial, is scheduled for December 14, 2026, at 11:15 AM CDT.
Why it matters
The data concern a CAR-T therapy for relapsed or refractory AL amyloidosis, a rare disease with limited treatment options in the United States. NXC-201 holds FDA Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations, and the presentation adds clinical data to the company's regulatory profile.
The presentation draws on a 45-patient study within a U.S. population of roughly 30,506 relapsed or refractory AL amyloidosis patients projected for 2026. The efficacy and safety results themselves are not detailed in the announcement, and their outcomes remain to be seen at the meeting.
The players
Immix Biopharma
Immix Biopharma is a Nasdaq-listed biopharmaceutical company developing NXC-201, a CAR-T therapy for AL amyloidosis.
American Society of Hematology (ASH)
The American Society of Hematology is a leading professional society for blood disorder research and clinical care, which hosts the annual meeting where the data will be shown.
The details
Immix Biopharma, listed on Nasdaq under the ticker IMMX, will present Publication #826 in session 652 on MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias. NXC-201 is a BCMA-targeted CAR-T cell therapy that uses a proprietary digital filter designed to limit non-specific activation.
Timeline
December 12-15, 2026: 68th ASH Annual Meeting in New Orleans
December 14, 2026, 11:15 AM CDT: NXC-201 oral presentation
Industry Context
BCMA-targeted CAR-T therapies have established a development path that NXC-201 extends into AL amyloidosis, a rare plasma cell disorder. The 45-patient Nexicart-2 study adds U.S. clinical data to that indication, which has a projected $6.6 billion market in 2026.
For patients with relapsed or refractory AL amyloidosis, the data may signal a future CAR-T option, though NXC-201 is not yet an approved treatment. Patients and clinicians should watch for regulatory developments and the full trial results once presented.
The takeaway
Investors and clinicians tracking rare-disease cell therapies should note the December 14 presentation as the first detailed public look at Nexicart-2 outcomes. Results from a 45-patient study will require confirmation in larger trials before conclusions about efficacy can be drawn.
What happens next
NXC-201 data will be presented at the 68th ASH Annual Meeting on December 14, 2026, at 11:15 AM CDT in New Orleans.
Further reading
For more on the sector, see Healthcare coverage across the United States.
Source note: This article includes information reported by The Manila times.
